Drugs / BMS-936559
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02576457 | Dec 2015 → Mar 2017 | infectious disease with sepsis | Bristol-Myers Squibb | Terminated | No outcome recorded Stop: Business |
| Phase 1 | NCT02028403 | Jun 2014 → Nov 2015 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01452334 | Nov 2011 → Nov 2014 | Hodgkins lymphoma, chronic myeloid leukemia, non-Hodgkin lymphoma, plasma cell myeloma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT01455103 | Nov 2011 → Nov 2013 | melanoma | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT00729664 | Feb 2009 → Jul 2015 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2012-06-02 | Bristol-Myers Squibb | Results Investigational Anti-PD-1 Immunotherapy BMS-936558 Showed Clinical Activity in Phase 1 Trial of Patients with Previously-Treated Non-Small-Cell Lung Cancer, Metastatic Melanoma and Renal Cell Cancer bms.com ↗
Data on a second investigational immunotherapy from Bristol-Myers Squibb, anti-PD-L1 (BMS-936559), were also published today in the New England Journal of Medicine 2 and featured in an oral presentation at ASCO (Abstract # 2510). |
All press releases naming this drug 1 release
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMS-936559 | “A Phase 1, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors” NCT00729664 ↗ |
| Known as | Anti-pdl-1 antibody bms-936559 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297702 ↗ |
| Known as | MDX-1105 | “A Phase 1, Multidose Study of BMS-936559 (MDX-1105) Administered Every 14 Days in Subjects With Selected Advanced or Recurrent Solid Tumors” NCT00729664 ↗ |
| Action | Inhibit | “Antibody-mediated blockade of PD-L1 induced durable tumor regression” PMID 22658128 ↗ Jun 2012 |
| Modality | Monoclonal antibody | “a fully human monoclonal IgG4 antibody targeting the Programed Death-Ligand 1 (PD-L1)” NCT00729664 ↗ |
| Route | Intravenous | “we administered intravenous anti-PD-L1 antibody” PMID 22658128 ↗ Jun 2012 |
| Target | CD274 | “antiprogrammed cell death-ligand 1 immune checkpoint inhibitor (BMS-936559; Bristol-Myers Squibb, Princeton, NJ)” PMID 30747773 ↗ May 2019 |